1,524 top medical experts on Urologic Neoplasms across 46 countries and 40 U.S. states, including 1,468 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Urologic Neoplasms: Tumors or cancer of the urinary tract in either the male or the female.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Urogenital Neoplasms (2,645), Urologic Diseases (1,579) and Narrower Categories: Kidney Neoplasms (5,066), Ureteral Neoplasms (1,461), Urethral Neoplasms (1,572), Urinary Bladder Neoplasms (4,264).
  4. Clinical Trials ClinicalTrials.gov : at least 93 including 9 Active, 35 Completed, 25 Recruiting
  5. Synonyms: Cancer of Urinary Tract,  Urinary Tract Cancer,  Urologic Cancer


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Rosenberg, Jonathan E   Internal Medicine   Google Publications
    Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial 
    Disclosed payments in 2021 from 27 biomedical companies, totalling $37,922.95, including $15,115.99 from  Astellas Pharma Global Development
    Subjects: Carcinoma, Transitional Cell; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents; Carcinoma
    Categories: Drug Therapy; Therapeutic Use; Genetics; Administration & Dosage; Pathology; Metabolism
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. (2018)

  2. Petrylak, Daniel Peter   Medical Oncology   ClinicalTrials.gov Google Publications
    Medical Oncology, Yale Cancer Center, Medical Oncology, New Haven, CT, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University (MD, 1985)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 96 biomedical companies, totalling $90,146.67, including $20,761.43 from  Astellas Pharma Global Development
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Antibodies, Monoclonal; Antineoplastic Agents; Antibodies, Monoclonal, Humanized
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Antagonists & Inhibitors; Genetics; Metabolism
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. (2017)

  3. Galsky, Matthew D   Medical Oncology   Google Publications
    Icahn School of Medicine at Mount Sinai, New York, NY, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Medical school: Tufts University School of Medicine (MD, 1998)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 72.4/100
    Disclosed payments in 2021 from 42 biomedical companies, totalling $79,966.11, including $17,087.5 from  E.R. Squibb & Sons, L.L.C.
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Antineoplastic Agents, Immunological
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Antagonists & Inhibitors; Methods; Pathology
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. (2017)

  4. Bajorin, Dean F   Medical Oncology   Google Publications
    Genitourinary Medical Oncology Service, Departments of Medicine.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: New York Medical College (MD, 1978)
    Medicare Accepted
    Disclosed payments in 2021 from 7 biomedical companies, totalling $9,959.24, including $5,271.74 from  Merck Sharp & Dohme Corporation
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal, Humanized; B7-H1 Antigen
    Categories: Drug Therapy; Therapeutic Use; Genetics; Antagonists & Inhibitors; Administration & Dosage; Epidemiology
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. (2017)

  5. Necchi, Andrea     Google Publications
    Department of Urology, IRCCS San Raffaele Hospital, & Vita Salute San Raffaele University, Milano, 20132, Italy.
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Cisplatin
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Genetics; Methods; Antagonists & Inhibitors
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. (2017)

  6. Powles, Thomas     Google Publications
    Barts Cancer Institute, QMUL, Barts Cancer Centre, London, UK. .
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Antagonists & Inhibitors; Methods; Mortality
    TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. (2018)
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. (2017)

  7. Grivas, Petros D   Medical Oncology   Google Publications
    University of Washington, Seattle, WA, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Disclosed payments in 2021 from 62 biomedical companies, totalling $128,813.69, including $41,897.6 from  EMD Serono, Inc.
    Subjects: Carcinoma, Transitional Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antibodies, Monoclonal; Antineoplastic Agents
    Categories: Therapeutic Use; Drug Therapy; Genetics; Metabolism; Antagonists & Inhibitors; Administration & Dosage
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. (2017)

  8. Balar, Arjun Vasant   Medical Oncology   Google Publications
    Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 86/100
    Disclosed payments in 2021 from 23 biomedical companies, totalling $43,228.68, including $23,175.87 from  Merck Sharp & Dohme Corporation
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Antagonists & Inhibitors; Genetics; Therapy
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. (2017)

  9. Vogelzang, Nicholas J   Hematology & Oncology  Google Publications
    Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (MD, 1974)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 100/100
    Disclosed payments in 2021 from 77 biomedical companies, totalling $95,083.23, including $30,293.72 from  GENZYME CORPORATION
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Taxoids
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Genetics; Antagonists & Inhibitors; Adverse Effects
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. (2017)
    Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. (2018)

  10. Quinn, David I   Medical Oncology   Google Publications
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Other (MD, 1987)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 77/100
    Disclosed payments in 2021 from 21 biomedical companies, totalling $29,816.21, including $9,315 from  Merck Sharp & Dohme Corporation
    Subjects: Antineoplastic Agents; Carcinoma, Transitional Cell; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Genetics; Metabolism; Antagonists & Inhibitors
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. (2017)
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. (2017)

  11. Dreicer, Robert   Medical Oncology   Google Publications
    University of Virginia Cancer Center, Charlottesville, VA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: University of Texas Medical School at Houston (MD, 1983)
    Medicare Accepted
    Disclosed payments in 2021 from 21 biomedical companies, totalling $37,489.35, including $9,794.12 from  PFIZER INC.
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Cisplatin
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Analysis; Antagonists & Inhibitors; Drug Effects
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. (2017)

  12. Sternberg, Cora N   Medical Oncology   Google Publications
    Weill Cornell Medicine, New York, NY.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Disclosed payments in 2021 from 61 biomedical companies, totalling $55,854.8, including $22,652.09 from  PFIZER INC.
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Genetics; Adverse Effects; Analogs & Derivatives
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. (2017)
    Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. (2020)

  13. Castellano, Daniel E     Google Publications
    Hospital Universitario 12 de Octubre, Madrid, Spain.
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Subjects: Carcinoma, Transitional Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents, Immunological; Antibodies, Monoclonal
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Mortality; Adverse Effects; Analogs & Derivatives
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. (2018)

  14. Choueiri, Toni K   Medical Oncology   ClinicalTrials.gov Google Publications
    Dana-Farber Cancer Institute, Boston, Massachusetts. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Disclosed payments in 2021 from 12 biomedical companies, totalling $27,297.2, including $14,250 from  Merck Sharp & Dohme Corporation
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Urothelium; Antineoplastic Agents
    Categories: Drug Therapy; Therapeutic Use; Genetics; Metabolism; Methods; Administration & Dosage
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. (2017)
    Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. (2019)

  15. Plimack, Elizabeth R   Medical Oncology   Google Publications
    Fox Chase Cancer Center, Philadelphia, PA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: New York Medical College (MD, 2002)
    Medicare Accepted
    Disclosed payments in 2021 from 19 biomedical companies, totalling $34,444, including $8,080 from  Merck Sharp & Dohme Corporation
    Subjects: Carcinoma, Transitional Cell; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antineoplastic Agents; Immunotherapy
    Categories: Drug Therapy; Therapeutic Use; Blood; Drug Effects; Pathology; Therapy
    Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. (2017)
    First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. (2017)

  16. Fong, Lawrence   Medical Oncology  Google Publications
    Medicine, University of California San Francisco, San Francisco, California, USA. Top Hospital
    Physician  Highly Cited  Clinical Trial 
    Medical school: Stanford University School of Medicine (MD, 1992)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 86/100
    Disclosed payments in 2021 from 8 biomedical companies, totalling $364,716.14, including $348,066.39 from  Amgen Inc.
    Subjects: Antibodies, Monoclonal; Urothelium; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols
    Categories: Drug Therapy; Therapeutic Use; Antagonists & Inhibitors; Drug Effects; Genetics; Immunology
    TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. (2018)
    Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. (2017)

  17. Vaishampayan, Ulka N   Internal Medicine  Google Publications
    Karmanos Cancer Institute, Detroit, MI, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Other (MD, 1993)
    Medicare Accepted
    Disclosed payments in 2021 from 52 biomedical companies, totalling $86,771.2, including $35,950.18 from  Exelixis Inc.
    Subjects: Carcinoma, Transitional Cell; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Pyrimidines; Carcinoma
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Genetics; Mortality; Therapy
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. (2017)
    Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with (2018)

  18. Hoffman-Censits, Jean H     Google Publications
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Departments of Medical Oncology and Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD. Electronic address: .
    Physician  Highly Cited  Clinical Trial 
    Subjects: Antibodies, Monoclonal; Carcinoma, Transitional Cell; Antineoplastic Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Pathology; Antagonists & Inhibitors; Genetics
    Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. (2016)
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. (2017)

  19. Pal, Sumanta Kumar   Medical Oncology   Google Publications
    Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Disclosed payments in 2021 from 8 biomedical companies, totalling $1,843.55, including $1,089.89 from  F. Hoffmann-La Roche AG
    Subjects: Carcinoma, Transitional Cell; Mutation; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Antibodies, Monoclonal
    Categories: Drug Therapy; Genetics; Therapeutic Use; Administration & Dosage; Drug Effects; Pathology
    Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. (2017)
    Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with (2018)

  20. Tagawa, Scott T   Hematology & Oncology   Google Publications
    Weill Cornell Medical College, New York, NY.
    Physician  Highly Cited  Clinical Trial 
    Medical school: University of Southern California Keck School of Medicine (MD, 1998)
    Medicare Accepted
    Disclosed payments in 2021 from 21 biomedical companies, totalling $36,460.33, including $8,424.44 from  PFIZER INC.
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Antineoplastic Agents; Receptors, Fibroblast Growth Factor; Angiogenesis Inhibitors
    Categories: Therapeutic Use; Drug Therapy; Administration & Dosage; Genetics; Antagonists & Inhibitors; Mortality
    Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. (2019)
    TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. (2021)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);